Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).

Authors
Publication date
1 April 2019
Publisher
Providence St. Joseph Health Digital Commons

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Providence St. Joseph Health Digital Commons

    redirect
    oaioai:digitalcommons.providence....
    Last time updated on 17/10/2023